Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AB Science SA and Skuldtech Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment


Monday, 5 Nov 2012 02:30am EST 

AB Science SA and Skuldtech announced the discovery of a new set of blood markers predictive of a higher survival rate in pancreatic cancer patients. Skuldtech and AB Science SA plan to exploit these new markers for commercialization of a future companion test associated with masitinib, a molecule developed by AB Science SA for treating pancreatic cancer. Based on Skuldtech’s technological approach associating gene sequencing with the company’s bioinformatics tools and gene profiling studies (transcriptome), these findings were made during a phase III clinical trial focusing on pancreatic cancer and managed by AB Science SA. The purpose of the phase III study was to evaluate the therapeutic efficiency of a new treatment combining masitinib and gemcitabine as compared with the current standard pancreatic cancer treatment of gemcitabine only. From a simple drop of blood, Skuldtech and AB Science SA were able to identify specific markers – transcriptomic markers – that can distinguish between the different populations treated during the phase III study and select the predictive markers for pancreatic cancer survival associated with masitinib treatment. 

Company Quote

11.66
0.17 +1.48%
16 Apr 2014